Last reviewed · How we verify
Rifampicin Only Product in Parenteral Dose Form
Rifampicin Only Product in Parenteral Dose Form is a Small molecule drug developed by Fundacion Clinic per a la Recerca Biomédica. It is currently FDA-approved.
At a glance
| Generic name | Rifampicin Only Product in Parenteral Dose Form |
|---|---|
| Sponsor | Fundacion Clinic per a la Recerca Biomédica |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rifampicin Only Product in Parenteral Dose Form CI brief — competitive landscape report
- Rifampicin Only Product in Parenteral Dose Form updates RSS · CI watch RSS
- Fundacion Clinic per a la Recerca Biomédica portfolio CI
Frequently asked questions about Rifampicin Only Product in Parenteral Dose Form
What is Rifampicin Only Product in Parenteral Dose Form?
Rifampicin Only Product in Parenteral Dose Form is a Small molecule drug developed by Fundacion Clinic per a la Recerca Biomédica.
Who makes Rifampicin Only Product in Parenteral Dose Form?
Rifampicin Only Product in Parenteral Dose Form is developed and marketed by Fundacion Clinic per a la Recerca Biomédica (see full Fundacion Clinic per a la Recerca Biomédica pipeline at /company/fundacion-clinic-per-a-la-recerca-biom-dica).
What development phase is Rifampicin Only Product in Parenteral Dose Form in?
Rifampicin Only Product in Parenteral Dose Form is FDA-approved (marketed).